| P50 | author | Joseph Sparano | Q56376696 |
| P2093 | author name string | David L Brown | |
| | Antonio C Wolff | |
| P2860 | cites work | Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes | Q24308695 |
| | Humanization of an anti-p185HER2 antibody for human cancer therapy | Q24561842 |
| | A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor | Q24648517 |
| | Implications of troponin testing in clinical medicine | Q24793067 |
| | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 |
| | Risk factors for doxorubicin-induced congestive heart failure | Q28328220 |
| | Anthracycline cardiomyopathy monitored by morphologic changes | Q28332787 |
| | Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma | Q28370603 |
| | Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes | Q28570675 |
| | ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice | Q28590176 |
| | ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer | Q28678776 |
| | The role of iron in doxorubicin-induced cardiomyopathy. | Q30472660 |
| | Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation | Q31780613 |
| | Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial | Q31826097 |
| | Usefulness of cardiac troponin I in patients undergoing open heart surgery | Q32083507 |
| | Endomyocardial biopsy to monitor anthracycline therapy in children | Q70942289 |
| | Anthracycline-induced cardiotoxicity | Q71112913 |
| | Serum cardiac troponin T levels during treatment of early-stage breast cancer | Q71832948 |
| | Metaanalysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart diseases | Q71939663 |
| | Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I | Q72019081 |
| | Rapid Ventricular Induction of Brain Natriuretic Peptide Gene Expression in Experimental Acute Myocardial Infarction | Q72034131 |
| | Assessment of anthracycline cardiomyopathy by endomyocardial biopsy | Q72444961 |
| | Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children | Q73181401 |
| | Cardiac troponin I in pediatrics: normal values and potential use in the assessment of cardiac injury | Q73457472 |
| | Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock | Q73742930 |
| | Cardiac troponin T in patients with clinically suspected myocarditis | Q73832142 |
| | Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care | Q73868164 |
| | Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study | Q74017016 |
| | Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction | Q74347919 |
| | Cardiac troponin I and N-terminal pro-brain natriuretic peptide in umbilical artery blood in relation to fetal heart rate abnormalities during labor | Q74434211 |
| | Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli | Q77093344 |
| | The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin | Q77306436 |
| | Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q77347398 |
| | Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations | Q77398814 |
| | Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women | Q77435888 |
| | Clinically significant blunt cardiac trauma: role of serum troponin levels combined with electrocardiographic findings | Q95720999 |
| | Effects of implantable cardioverter defibrillator implantation and shock application on biochemical markers of myocardial damage. | Q32129818 |
| | Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy | Q33180853 |
| | Basic science of HER-2/neu: a review | Q33730971 |
| | Cardiac troponins in congestive heart failure | Q33741038 |
| | Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction | Q33917874 |
| | Cardiac natriuretic peptides--hope or hype? | Q34207401 |
| | Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials | Q34218140 |
| | Cardiac natriuretic peptides: new laboratory parameters in heart failure patients. | Q34281248 |
| | Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. | Q34429779 |
| | Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin | Q34718010 |
| | Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population | Q35380181 |
| | Outcome of clinical congestive heart failure induced by anthracycline chemotherapy | Q35474572 |
| | Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens | Q35976425 |
| | Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer. | Q36641347 |
| | The Regulation of Contractile Activity in Muscle | Q39893178 |
| | Cardiac toxicity 4 to 20 years after completing anthracycline therapy | Q41142694 |
| | Involvement of the neuregulins and their receptors in cardiac and neural development | Q41270162 |
| | Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy | Q41677472 |
| | Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity | Q42253680 |
| | Adult multicenter trials using dexrazoxane to protect against cardiac toxicity | Q42539061 |
| | Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity | Q42545430 |
| | Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. | Q42546809 |
| | Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors | Q43511361 |
| | Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity | Q43560510 |
| | Minor myocardial injury after elective uncomplicated successful PTCA with or without stenting: detection by cardiac troponins | Q43626874 |
| | Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group | Q43636271 |
| | Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer | Q43683844 |
| | Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction | Q43703660 |
| | New serum markers for acute myocardial infarction. | Q44643012 |
| | Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation | Q47671905 |
| | Elevated B-type natriuretic peptide levels after anthracycline administration | Q47685522 |
| | Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain. | Q47822631 |
| | Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies | Q47913580 |
| | Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group | Q48282773 |
| | Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients | Q48327981 |
| | Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea | Q48765319 |
| | Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction | Q48958058 |
| | Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. | Q54029917 |
| | Detection of myocardial injury during radiofrequency catheter ablation by measuring serum cardiac troponin I levels: procedural correlates | Q61669147 |
| | Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction | Q67989508 |
| | Influence of reperfusion on serum concentrations of cytosolic creatine kinase and structural myosin light chains in acute myocardial infarction | Q69258609 |
| | Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death | Q70014087 |
| | Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion | Q70058588 |
| P433 | issue | 5 | |
| P304 | page(s) | 301-311 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers | |
| P478 | volume | 25 | |